Form 4: Belite Bio Insider Sells Shares Under 10b5-1 Plan

Belite Bio's Chief Scientific Officer, Nathan L. Mata, reported the sale of American depositary shares valued at over $1.2 million through a pre-arranged trading plan.

Summary

• Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., reported the sale of American depositary shares (ADS) on April 27, 2026.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025.
• A total of 1,276 ADS were sold across multiple transactions with weighted average prices ranging from $160.54 to $164.59.
• The total value of the reported sales is approximately $1,200,000.
• Following these transactions, Mata beneficially owns 7,666 ADS.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as the reported sales were executed under a pre-established Rule 10b5-1 trading plan, mitigating concerns of insider trading, though any insider selling can be a point of observation for investors.

Negatives

• Insider selling activity, particularly by a Chief Scientific Officer, can sometimes be interpreted negatively by the market, although in this case it was conducted under a pre-established plan.

Risks

• The sales were conducted under a Rule 10b5-1 plan, which is designed to mitigate insider trading concerns, but the act of selling by a key executive could still be perceived as a lack of confidence in near-term stock performance by some investors.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common and are intended to provide a defense against allegations of insider trading. However, the volume and timing of such sales by key executives can still influence investor sentiment.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe the insider selling activity, though the Rule 10b5-1 plan mitigates direct concerns about insider trading. The impact on share price is not directly predictable from this filing alone.
• Employees: No direct impact mentioned.
• Management: Nathan L. Mata is executing a pre-planned strategy for managing his personal holdings.

Next Steps

• Continued monitoring of insider transactions for any further sales or purchases.
• Observation of Belite Bio's stock performance and corporate developments.

Key Dates

Keywords

Belite Bio, BLTE, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Nathan L. Mata, Chief Scientific Officer, American Depositary Shares